CBD Life Sciences, Inc. (CBDL) Announces MOU With New York Dispensary, Poised for Significant Revenue Growth and Shareholder Value
CBD Life Sciences, Inc. (OTC PINK:CBDL) has signed a Memorandum of Understanding (MOU) to acquire a 45% ownership interest in a state-licensed Cannabis Dispensary in New York. The targeted acquisition has an estimated business value of $10 million with projected 2024 gross revenues of up to $4.5 million. The dispensary, expected to be located on Long Island, is positioned to become a key revenue generator for CBDL.
This strategic move aligns with CBDL's commitment to growth and expanding its footprint in the Northeast region. The company will be entitled to a share of the monthly profits from the dispensary's operations, subject to necessary approvals and finalization of a formal agreement. CEO Lisa Nelson expressed confidence that this endeavor will drive considerable revenue growth and reinforce CBDL's leadership in the industry.
CBD Life Sciences, Inc. (OTC PINK:CBDL) ha firmato un Memorandum of Understanding (MOU) per acquisire un 45% di partecipazione in un dispensario di cannabis autorizzato nello stato di New York. L'acquisizione mirata ha un valore commerciale stimato di $10 milioni con ricavi lordi previsti per il 2024 fino a $4,5 milioni. Si prevede che il dispensario si trovi a Long Island e diventi un importante generatore di entrate per CBDL.
Questa mossa strategica è in linea con l'impegno di CBDL per la crescita e l'espansione della sua presenza nella regione del Northeast. L'azienda avrà diritto a una quota dei profitti mensili derivanti dalle operazioni del dispensario, soggetti alle necessarie approvazioni e alla finalizzazione di un contratto formale. Il CEO Lisa Nelson ha espresso fiducia che questa iniziativa porterà a una considerevole crescita dei ricavi e consoliderà la leadership di CBDL nel settore.
CBD Life Sciences, Inc. (OTC PINK:CBDL) ha firmado un Memorando de Entendimiento (MOU) para adquirir un 45% de participación en un dispensario de cannabis con licencia estatal en Nueva York. La adquisición objetivo tiene un valor comercial estimado de $10 millones con ingresos brutos proyectados para 2024 de hasta $4,5 millones. Se espera que el dispensario se ubique en Long Island y se convierta en un generador clave de ingresos para CBDL.
Este movimiento estratégico se alinea con el compromiso de CBDL con el crecimiento y la expansión de su huella en la región del Noreste. La empresa tendrá derecho a una parte de las ganancias mensuales de las operaciones del dispensario, sujeto a las aprobaciones necesarias y a la finalización de un acuerdo formal. La CEO Lisa Nelson expresó confianza en que este esfuerzo impulsará un crecimiento considerable de los ingresos y reforzará el liderazgo de CBDL en la industria.
CBD 라이프 사이언스(CBD Life Sciences, Inc.)(OTC PINK:CBDL)는 45%의 지분을 뉴욕주에서 허가받은 대마초 판매점에 인수하기 위한 양해각서(MOU)를 체결했습니다. 이 목표 인수의 예상 사업 가치는 1천만 달러이며, 2024년 총 수익은 최대 450만 달러에 이를 것으로 예상됩니다. 판매점은 롱 아일랜드에 위치할 것으로 예상되며 CBDL의 주요 수익원으로 자리잡을 것입니다.
이 전략적 움직임은 CBDL의 성장과 북동부 지역에서의 입지 확대에 대한 약속과 일치합니다. 이 회사는 판매점 운영에서 발생하는 월별 수익의 일부를 받을 권리를 가지며, 필요 승인 및 공식 계약 최종화가 필요합니다. CEO 리사 넬슨은 이번 사업이 상당한 수익 성장을 이끌고 CBDL의 업계 리더십을 강화할 것이라고 확신했습니다.
CBD Life Sciences, Inc. (OTC PINK:CBDL) a signé un protocole d'accord (MOU) pour acquérir un 45% de participation dans un dispensaire de cannabis agréé par l'État à New York. L'acquisition ciblée a une valeur commerciale estimée à 10 millions de dollars, avec des revenus bruts prévus pour 2024 allant jusqu'à 4,5 millions de dollars. Le dispensaire, qui devrait être situé à Long Island, est positionné pour devenir un moteur de revenus clé pour CBDL.
Ce mouvement stratégique s'aligne avec l'engagement de CBDL pour la croissance et l'expansion de sa présence dans la région du Nord-Est. L'entreprise aura droit à une part des bénéfices mensuels issus des opérations du dispensaire, sous réserve des approbations nécessaires et de la finalisation d'un accord formel. La PDG Lisa Nelson a exprimé sa confiance que cette initiative stimulera une croissance considérable des revenus et renforcera le leadership de CBDL dans l'industrie.
CBD Life Sciences, Inc. (OTC PINK:CBDL) hat ein Memorandum of Understanding (MOU) unterzeichnet, um einen 45%igen Anteil an einem staatlich lizenzierten Cannabis-Dispensary in New York zu erwerben. Der angestrebte Erwerb hat einen geschätzten Unternehmenswert von 10 Millionen Dollar bei einem prognostizierten Bruttoumsatz von bis zu 4,5 Millionen Dollar für 2024. Das Dispensary, das voraussichtlich auf Long Island angesiedelt sein wird, ist positioniert, um ein wichtiger Umsatzgenerator für CBDL zu werden.
Dieser strategische Schritt stimmt mit CBDLs Engagement für Wachstum und die Expansion im Nordosten überein. Das Unternehmen wird berechtigt sein, einen Anteil an den monatlichen Gewinnen aus dem Betrieb des Dispensary zu erhalten, vorbehaltlich der erforderlichen Genehmigungen und der Finalisierung eines formellen Vertrags. CEO Lisa Nelson äußerte Vertrauen, dass dieses Vorhaben erhebliches Umsatzwachstum fördern und CBDLs Führungsposition in der Branche stärken wird.
- Potential acquisition of 45% ownership in a New York cannabis dispensary
- Targeted acquisition has an estimated business value of $10 million
- Projected 2024 gross revenues of up to $4.5 million for the dispensary
- Expected to generate significant revenue for CBD Life Sciences
- Expansion into the lucrative New York cannabis market
- Acquisition is subject to necessary approvals and finalization of a formal agreement
- Projected revenues are estimates and not guaranteed
The targeted acquisition is estimated to have a business value of approximately
SCOTTSDALE, AZ / ACCESSWIRE / August 29, 2024 / CBD Life Sciences, Inc. (OTC PINK:CBDL), a leading publicly traded company in the CBD industry, is pleased to announce the signing of a Memorandum of Understanding (MOU) with a prominent entity in the cannabis sector. This strategic agreement signifies a pivotal moment in CBD Life Sciences' ongoing efforts to expand its footprint in the burgeoning New York market.
The MOU outlines the potential acquisition of a
"We are thrilled about the potential this MOU holds for CBD Life Sciences and our shareholders," said Lisa Nelson, President and CEO of CBD Life Sciences, Inc. "Securing a foothold in New York's dynamic cannabis market is a strategic move that aligns with our commitment to growth and delivering substantial returns to our investors. We are confident that this endeavor will drive considerable revenue growth and reinforce our leadership in the industry."
As part of the agreement, CBD Life Sciences, Inc. will be entitled to a share of the monthly profits from the dispensary's operations, subject to the completion of necessary approvals and the finalization of a formal, binding agreement. This expected revenue stream is in line with the company's strategy to maximize investor value while pursuing long-term sustainable growth.
CBD Life Sciences, Inc. continues to demonstrate its ability to leverage strategic partnerships and acquisitions to propel its business forward. This latest initiative is expected to solidify the company's competitive advantage and establish a strong presence in the lucrative New York cannabis market.
"We believe this strategic expansion will enhance our financial position and allow us to continue delivering consistent value to our shareholders," added Nelson. "Our mission remains clear: to expand our reach, increase profitability, and create long-term value for everyone involved."
About CBD Life Sciences, Inc.
The CBD Vault Inc. is a wholly owned subsidiary of CBD Life Sciences Inc. The CBD Vault has developed and is retailing/wholesale a full line of cannabidiol based & organic products including, Delta 8 & 10 Gummy's, Full Spectrum Tinctures & Gummy's, Pain Cream, Roll-on's, Salve, Full Pet Line, Pre-Rolls, Full Line of Spa Products, Sleep & Anxiety Edibles. The CBD Vault's products can be viewed and purchased on the Company's website www.thecbdvault.com.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
FAQ
What is the estimated business value of the dispensary CBDL plans to acquire?
What percentage ownership is CBDL seeking in the New York dispensary?
What are the projected 2024 gross revenues for the dispensary CBDL plans to acquire?
Where in New York is the dispensary expected to be located?
